
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
This trial looked at a drug called vorinostat (also known as MK0683) for mesothelioma of the lung that continued to grow despite having chemotherapy.
The results of this trial were published in 2015.
The trial team found that giving people with mesothelioma of the lung (pleural mesothelioma) vorinostat after chemotherapy did not improve the length of time they lived for. They do not recommend it as a treatment for people with advanced pleural mesothelioma.
This was an international phase 3 trial. 661 people in 24 countries took part.
The trial was randomised. The people taking part were put into treatment groups by a computer. Neither they nor their doctor could decide which group they were in.
Half the people taking part had vorinostat capsules. The other half had capsules that contain a dummy drug (placebo).
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Paul Robinson
Experimental Cancer Medicine Centre (ECMC)
Merck
Sharp & Dohme
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”